Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuping Yin

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
SLAS Discovery : Advancing Life Sciences R & D|March 16, 2017
Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based ScreeningLihong Zhang, Jianfeng Shen, Yuping Yin, et al.
Cancer Science|March 5, 2020
Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axisShaofei Chen, Guobin Wang, Kaixiong Tao, et al.
Annals of Surgical Oncology|August 17, 2024
Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 TrialXiong Sun, Jianbo Lyu, Ming Yang, et al.
Frontiers in Oncology|September 26, 2022
Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trialYuping Yin, Yao Lin, Ming Yang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 2, 2025
Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade EfficacyYao Lin, Xiong Sun, Chengguo Li, et al.
Cancer Science|September 13, 2023
Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancerTao Wang, Weizhen Liu, Qian Shen, et al.
Molecular Cancer Therapeutics|May 31, 2019
The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric CancerYuping Yin, Weizhen Liu, Qian Shen, et al.
American Journal of Cancer Research|April 13, 2017
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancerYuping Yin, Qian Shen, Peng Zhang, et al.
Cell Reports. Medicine|March 18, 2026
Neuroprotective response against the onset of ischemic stroke by upregulation of histone H3Y99 sulfationLi Jiang, Junchang Xie, Jianfeng Wang, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
SLAS Discovery : Advancing Life Sciences R & D|March 16, 2017
Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based ScreeningLihong Zhang, Jianfeng Shen, Yuping Yin, et al.
Cancer Science|March 5, 2020
Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axisShaofei Chen, Guobin Wang, Kaixiong Tao, et al.
Annals of Surgical Oncology|August 17, 2024
Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 TrialXiong Sun, Jianbo Lyu, Ming Yang, et al.
Frontiers in Oncology|September 26, 2022
Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trialYuping Yin, Yao Lin, Ming Yang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 2, 2025
Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade EfficacyYao Lin, Xiong Sun, Chengguo Li, et al.
Cancer Science|September 13, 2023
Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancerTao Wang, Weizhen Liu, Qian Shen, et al.
Molecular Cancer Therapeutics|May 31, 2019
The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric CancerYuping Yin, Weizhen Liu, Qian Shen, et al.
American Journal of Cancer Research|April 13, 2017
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancerYuping Yin, Qian Shen, Peng Zhang, et al.
Cell Reports. Medicine|March 18, 2026
Neuroprotective response against the onset of ischemic stroke by upregulation of histone H3Y99 sulfationLi Jiang, Junchang Xie, Jianfeng Wang, et al.
Pageof 7